Enovis price target raised to $73 from $63 at Baird

Baird raised the firm’s price target on Enovis to $73 from $63 and keeps an Outperform rating on the shares. The firm said they remain comfortable with the company’s likely ability to sustain above-medtech growth in its core recon business and are also encouraged by early positives on the integration front with Lima.